SCM
UTHR icon

Suvretta Capital Management’s United Therapeutics UTHR Stock Holding History

Suvretta Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,500
Closed -$3.65M – 108
2025
Q4 		$3.65M Hold
7,500
– – 0.07% 71
2025
Q3 		$3.14M Buy
+7,500
New +$2.52M 0.08% 71
2024
Q1 		– Sell
-1,360
Closed -$299K – 113
2023
Q4 		$299K Hold
1,360
– – 0.01% 86
2023
Q3 		$307K Hold
1,360
– – 0.02% 86
2023
Q2 		$300K Hold
1,360
– – 0.02% 95
2023
Q1 		$305K Buy
+1,360
New +$335K 0.01% 91

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Suvretta Capital Management's UTHR Position: Q1 2026 in Review

Suvretta Capital Management sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 7,500 shares — an estimated $3.65M sold.

Suvretta Capital Management first reported a position in UTHR in Q1 2023 and held it in 6 quarters. The position peaked at $3.65M in Q4 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Suvretta Capital Management reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Suvretta Capital Management sold 7,500 United Therapeutics shares in Q1 2026, an estimated $3.65M.
  • Suvretta Capital Management first reported a position in United Therapeutics in Q1 2023 and held it in 6 quarters.
  • Suvretta Capital Management's United Therapeutics position peaked at $3.65M in Q4 2025.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.